Emergent BioSolutions (EBS) Reports Q3 results; updates guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.83 +3.65%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
ZTO, AMMX, AFIB, More
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
ZTO, AMMX, AFIB, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 Revenue for the quarter at $271 million versus the consensus estimate of $237.43 million.
GUIDANCE:
Emergent BioSolutions sees FY2023 revenue of $1-1.1 billion, versus the consensus of $1.04 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TJX stock drops as profit outlook falls short of analyst estimates
- VNET Group (VNET) Misses Q2 EPS by 164c
- uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
